01 August 2010
MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers
Mohamed El AyedBCD, David BonnelBCD, Remi LonguespéeBF, Céline CastelierB, Julien FranckBD, Daniele VergaraB, Annie DesmonsB, Aurélie TasiemskiB, Abderraouf KenaniEF, Denis VinatierAG, Robert DayEG, Isabelle FournierADEFG, Michel SalzetADEFGMed Sci Monit 2010; 16(8): BR233-245 :: ID: 881095
Abstract
Background: Among biomarkers, cancer-antigen 125 (CA-125) is the most studied. We propose an analytical tool to track ovarian carcinoma biomarkers, that is, the MALDI mass spectrometry imaging.
Material/Methods: Ovarian carcinomas and benign ovaries were directly analyzed by MALDI-TOF-MS. After automatic profiling and mass spectrometry imaging analyses, hierarchical clustering based on principal component analysis in nonsupervised mode was carried out. On the same samples, preparations were performed to investigate peptides, then proteins, followed by high mass proteins, in an automatic profiling to specific signatures for diagnosis. Using tissue bottom-up strategy on tissue digestion, and mass spectrometry imaging after by shotgun sequencing by nalano-LC-IT-MS in MS/MS mode from washing samples from on tissue digested peptides, several biomarkers were found.
Results: A list of specific biomarkers from the ovarian carcinoma regions was obtained and classified as proteins associated with cell proliferation, involved in immune response modulation, signaling to the cytoskeleton, and tumor progression. These specific biomarkers were then validated by immunocytochemistry using Tag-mass technology, cell biology, Western blot, and by PCR (using SKOV-3 ovarian epithelial cancer cells). A link between the immune regulation (innate immunity, tolerance) and virus cause is also discussed.
Conclusions: From the biomarkers identified, proteins involved in immune response modulation and cell proliferation have been pointed out in this study. Two new markers have been identified using such a strategy, that is, fragment C-terminal of the PSME1 (Reg-Alpha) and mucin-9.
Keywords: Principal Component Analysis, Ovarian Neoplasms - pathology, Neoplasm Proteins - metabolism, Nanotechnology, Molecular Weight, Molecular Sequence Data, Amino Acid Sequence, Adenocarcinoma, Mucinous, Reproducibility of Results, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods, Tumor Markers, Biological - metabolism
Editorial
01 March 2025 : Editorial
Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical TrialsDOI: 10.12659/MSM.948672
Med Sci Monit 2025; 31:e948672
In Press
Review article
Current Trends and Innovations in Oral and Maxillofacial ReconstructionMed Sci Monit In Press; DOI: 10.12659/MSM.947152
Clinical Research
The Role of the Vojta Method in Diagnosing and Enhancing Motor Skills in Preterm Infants: A Prospective Ope...Med Sci Monit In Press; DOI: 10.12659/MSM.945495
Clinical Research
Comparative Outcomes of Robot-Assisted vs Traditional Laparoscopic Ureteral Reimplantation for Lower Ureter...Med Sci Monit In Press; DOI: 10.12659/MSM.946803
Review article
Review of Paraneoplastic Syndromes in Children with MalignancyMed Sci Monit In Press; DOI: 10.12659/MSM.947393
Most Viewed Current Articles
17 Jan 2024 : Review article 7,423,618
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 702,452
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 28,015
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 22,430
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912